All In Biotech

Drug Trial Radar · NCT06932471

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

A Multicenter, Single-arm, Open-label Phase III Study to Evaluate Efficacy and Safety of MY008211A Tablets in Patients With PNH and Residual Anemia, Despite Treatment With Anti-C5 Antibody.

Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Aug 30, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • MY008211A tabletsDrug

    MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of Participants With Sustained Hemoglobin Levels of ≥ 120 g/L in the Absence of Red Blood Cell Transfusions (defined as no red blood cell infusion after D14 to D168)Time frame: between Day 126 and Day 168

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital (PUMCH).

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.